Quality of Life and Outcomes in Glioblastoma Management

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 507-513

  Colen, Chaim B ^a   Allcut, Elizabeth ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ethics; Glioblastoma; Health related quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; TEMOZOLOMIDE;

APHASIA; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; COGNITIVE DEFECT; DEMENTIA; DRUG INDUCED DISEASE; GLIOBLASTOMA; HEMIPARESIS; HOSPICE CARE; HUMAN; NEUROTOXICITY; PATIENT ATTITUDE; PHYSICAL DISABILITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEUROSURGICAL PROCEDURES; PALLIATIVE CARE; QUALITY OF LIFE; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84862993217     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.04.010     Document Type: Review

References (31)

1. Colen C.B., Shen Y., Ghoddoussi F., et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 2011, 13(7):620-632.
2. Colen C.B., Seraji-Bozorgzad N., Marples B., et al. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 2006, 59(6):1313-1323. [discussion: 1323-4].
3. Mauer M., Stupp R., Taphoorn M.J., et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer 2007, 97(3):302-307.
4. Garside R., Pitt M., Anderson R., et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007, 11(45):xi-xii. ix-221.
5. Bosma I., Reijneveld J.C., Douw L., et al. Health-related quality of life of long-term high-grade glioma survivors. Neuro Oncol 2009, 11(1):51-58.
6. Cheng J.X., Zhang X., Liu B.L. Health-related quality of life in patients with high-grade glioma. Neuro Oncol 2009, 11(1):41-50.
7. Herdman M. Med Clin (Barc) 2000, 114(Suppl):322-325. [in Spanish].
8. Osoba D., Brada M., Yung W.K., et al. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000, 18(7):1481-1491.
9. Torrance G.W., Feeny D.H., Furlong W.J., et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996, 34(7):702-722.
10. Yavas C., Zorlu F., Ozyigit G., et al. Health-related quality of life in high-grade glioma patients: a prospective single-center study. Support Care Cancer 2011, [Epub ahead of print].
11. Yavas C., Zorlu F., Ozyigit G., et al. Prospective assessment of health-related quality of life in patients with low-grade glioma: a single-center experience. Support Care Cancer 2011, [Epub ahead of print].
12. Taphoorn M.J., Sizoo E.M., Bottomley A. Review on quality of life issues in patients with primary brain tumors. Oncologist 2010, 15(6):618-626.
13. Herdman M., Fox-Rushby J., Badia X. A model of equivalence in the cultural adaptation of HRQoL instruments: the universalist approach. Qual Life Res 1998, 7(4):323-335.
14. Hammoud M.A., Sawaya R., Shi W., et al. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996, 27(1):65-73.
15. Oh J., Henry R.G., Pirzkall A., et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004, 19(5):546-554.
16. Li X., Jin H., Lu Y., et al. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004, 17(1):10-20.
17. Hobbs S.K., Shi G., Homer R., et al. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 2003, 18(5):530-536.
18. Ashby L.S., Ryken T.C. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 2006, 20(4):E3.
19. Wiesner S.M., Freese A., Ohlfest J.R. Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies. Neurosurg Focus 2005, 19(4):E3.
20. Stupp R., Hegi M.E., van den Bent M.J., et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 2006, 11(2):165-180.
21. Furlong W.J., Feeny D.H., Torrance G.W., et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001, 33(5):375-384.
22. Kondziolka D., Flickinger J.C., Bissonette D.J., et al. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 1997, 41(4):776-783. [discussion: 783-5].
23. Keime-Guibert F., Napolitano M., Delattre J.Y. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998, 245(11):695-708.
24. Crowley R.W., Pouratian N., Sheehan J.P. Gamma knife surgery for glioblastoma multiforme. Neurosurg Focus 2006, 20(4):E17.
25. Combs S.E., Widmer V., Thilmann C., et al. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 2005, 104(10):2168-2173.
26. Nicholas M.K. Glioblastoma multiforme: evidence-based approach to therapy. Expert Rev Anticancer Ther 2007, 7(Suppl 12):S23-S27.
27. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
28. Duffner P.K., Cohen M.E., Thomas P.R., et al. The long-term effects of cranial irradiation on the central nervous system. Cancer 1985, 56(Suppl 7):1841-1846.
29. Dietrich J., Han R., Yang Y., et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5(7):22.
30. Faithfull S., Cook K., Lucas C. Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided. Palliat Med 2005, 19(7):545-550.
31. Arber A., Faithfull S., Plaskota M., et al. A study of patients with a primary malignant brain tumour and their carers: symptoms and access to services. Int J Palliat Nurs 2010, 16(1):24-30.